Tag: Biopharma Strategy
-
Why AstraZeneca Investors Rejected a $400 Billion BMS Megadeal
Reports of a potential $400 billion AstraZeneca–Bristol Myers Squibb combination triggered a sharp market backlash and renewed questions about the value of Big Pharma megamergers.
-
Can GSK Deliver Its £40 Billion Growth Ambition?
GlaxoSmithKline (GSK) will unveil its long-term growth strategy on July 28. As CEO Luke Miels leads his first major investor event, the focus will be on whether oncology expansion and HIV transformation can realistically support the company’s £40 billion revenue ambition by 2031.